# A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

> **NCT01706783** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 35 (actual)

## Conditions studied

- Growth Hormone Disorder
- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** somapacitan
- **DRUG:** Norditropin NordiFlex®

## Key facts

- **NCT ID:** NCT01706783
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-12
- **Primary completion:** 2013-11-18
- **Final completion:** 2013-11-18
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706783, "A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01706783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*